OncoMatch/Clinical Trials/NCT02889666
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Is NCT02889666 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for recurrent non-small cell lung cancer.
Treatment: Cisplatin · Carboplatin · Docetaxel · Gemcitabine/Carboplatin · Gemcitabine/Cisplatin · Docetaxel/Oxaliplatin · Docetaxel/Carboplatin — The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage ≥ IA (T1A, N0, M0) (1997 revision of the International Union Against Cancer TNM staging system)
Excluded: Stage IV
A Clinical Stage ≥ IA (T1a, N0, M0) of lung disease but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer TNM staging system)
Performance status
WHO 0–1
Demographics
Prior therapy
Cannot have received: cancer chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02889666 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage ≥ IA (T1A, N0, M0) is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages